Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.55 |
| ▸ | HTR2B | P41595 | 20/20 | 0.55 |
| ▸ | HTR2A | P28223 | 14/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618588 | 1.00 | HTR2C (0.55) | HTR2CHTR2BHTR2A | |
| SCHEMBL5619702 | 1.00 | HTR2C (0.55) | HTR2CHTR2BHTR2A | |
| SCHEMBL31562964 | 0.80 | GRIA1 (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL13595221 | 0.77 | HTR2C (0.60) | HTR2CHTR2BHTR2A | |
| SCHEMBL31563001 | 0.77 | GRIA1 (0.58) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL4411108 | 0.76 | HTR2C (0.59) | HTR2CHTR2BHTR2A | |
| SCHEMBL8225952 | 0.75 | MAOB (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL11380531 | 0.71 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8596101 | 0.71 | HTR2C (0.72) | HTR2CHTR2BHTR2A | |
| SCHEMBL3661023 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTR2C 6/4885HTR2B 3/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.